Dipalma Stephen J.
SEC-identified person · CIK 1426479 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Spero Therapeutics, Inc. SPRO | See Remarks | filed 2019 - 2023 |
| Inozyme Pharma, Inc. INZY | Interim CFO | filed 2021 - 2021 |
| Solid Biosciences, LLC SLDB | Interim CFO | filed 2021 - 2021 |
| Generation Bio Co. GBIO | See Remarks | filed 2020 - 2020 |
| Chemomab Therapeutics Ltd. CMMB | Chief Financial Officer | filed 2020 - 2020 |
| Interleukin Genetics INC ILIU | Interim CFO | filed 2014 - 2016 |
| Scorpius Holdings, Inc. SCPX | Interim CFO | filed 2015 - 2015 |
| Sellas Life Sciences Group, Inc. gale | CFO, EVP, Secretary | filed 2008 - 2009 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.